Cabazitaxel versus Docetaxel Both With Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (FIRSTANA)

Objectives: Cabazitaxel (Jevtana) is approved for second-line treatment of metastatic prostate cancer in patients previously treated with docetaxel (Taxotere). This randomized phase III trial pits the two taxanes against each other in the first-line setting. Two doses of cabazitaxel (20 mg/m2 and 25 mg/m2) are explored; overall survival is the primary outcome.

Key entry or exclusion criteria: Patients with prior chemotherapy for prostate cancer are excluded.

Locations: 166 sites.

Goal: 1,170 patients.

Study sponsor: Sanofi-Aventis

Link for more information: clinicaltrials.gov/ct2/show/NCT01308567

NIH clinical trials identifier: NCT01308567